Alan Fields, Ph.D., leads a research laboratory interested in the genetics, biochemistry and cell biology of lung and colon cancers; and chronic myelogenous leukemia.
Currently, the laboratory is focused on the role members of the protein kinase C (PKC) family of protein kinases play in the initiation, promotion and metastatic spread of these cancers. Dr. Fields' team has developed cell and mouse models to help understand how specific PKC isozymes are involved in colon and lung carcinogenesis.
The results demonstrate that multiple PKC isozymes paly critical role sin cancer development, or carcinogenesis. The team has identified one PKC isozyme, PKCiota, that is required for transformed growth of human lung cancer cells in vitro and human lung cancer tumors grown in nude mice. They also have shown that PKCiota is overxpressed in human lung cancers and predicts poor survivalin patients with lung cancer.
This data demonstrates that PKCiota may be an important prognostic indicator and therapeutic target in lung cancer.
Dr. Fields' research program is included in GI Cancer and Pharmacology and Experimental Therapeutics within the Mayo Clinic Cancer Center.